EN DE
Watch Bilcare Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bilcare Limited (526853) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Bilcare Limited stock ₹44.81, price ₹86.07, that is 47.9% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Materials IN

BL Bilcare Limited logo Thin data Nov 12, 2026

Bilcare Limited

526853 · BSE

Far too expensive (fair value 48% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Solidly profitable · 13.6% net margin (TTM) 
Generates free cash flow 
Quality 59/100 
Revenue last quarter 77% below a year ago. 
Changed on Nov 13: ₹17.35 → ₹44.81 
Fair value ₹44.81 · Strongly overvalued 
Weak Growth (revenue 3y −9.3 %/yr in INR) 
High debt 
Trails peers (3/12) 
Narrow moat 34/100
Thin data 
Watch Bilcare Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹113.60 ₹32.10 Fair Value ₹44.81 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range ₹32.10 – ₹113.60 · fair‑value band ₹30.48 – ₹49.96 · the ₹86.07 price screens above the ₹44.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Bilcare in your weekly email

Every Wednesday you see whether Bilcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bilcare Limited provides pharmaceutical packaging research solutions and global clinical services in India and internationally.

Show moreShow less

The company offers various specialty polymer films and aluminum foils primarily used for packaging solid dosage pharmaceutical products; and other packaging films solutions for applications in ID card, specialty film, and food packaging industries.

It also provides clinical trial materials supplies and project management services; and nonClonableID, an anti-counterfeiting, security, and brand protection solution for various industry sectors. The company serves pharmaceutical and biotechnology industries.

Bilcare Limited was incorporated in 1987 and is based in Pune, India.

Stock analysis

Bilcare Limited (526853) currently trades at ₹86.07, while our model-based Fair Value estimate is ₹44.81, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of ₹73.28 per share, and 2 of the 17 models we run sit above the ₹86.07 price.

Bear case: the Earnings-Based group reads lowest at ₹6.07, and 15 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹30.48 (bear) to ₹49.96 (bull), the price of ₹86.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Bilcare Limited reported revenue of ₹7.3B in FY2026 versus ₹8.4B in FY2022, a compound −3.5%/yr. Reported net income was ₹17.2M in FY2026.

Key figures

Market cap ₹2.0B (≈ $21.6M) Micro · P/S ratio 0.15 · EPS (TTM) ₹41.68 · Net margin 13.6% · Return on assets (EBIT) 4.1% (5-year average) · Operating margin 1.0% · Revenue (TTM) ₹7.2B · Revenue growth (YoY) −76.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).

What moves the price

The share trades about 22% below its 52-week high and 66% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Materials peers we cover trades at 6% fair-value upside, at −48%, 526853 screens richer than that median.

Fair Value models

Bear ₹30.48 Fair Value ₹44.81 Bull ₹49.96
Price ₹86.07 · Downside -47.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹26.38 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹76.30 ₹104.33 ₹148.40 80
Growth DCF ₹78.81 ₹105.00 ₹143.17 78
5Y EBITDA Exit ₹30.48 ₹44.81 ₹63.87 74
All 17 models by family
DCF Models
FCF DCF ₹76.30 ₹104.33 ₹148.40 80
Owner Earnings ₹18.32 ₹32.92 ₹55.87 73
5Y Revenue Exit ₹26.52 ₹37.97 ₹54.25 72
5Y EBITDA Exit ₹30.48 ₹44.81 ₹63.87 74
5Y P/E Exit ₹20.19 ₹27.05 ₹35.83 71
10Y Revenue Exit ₹50.85 ₹60.47 ₹69.07 67
10Y EBITDA Exit ₹53.19 ₹63.89 ₹73.63 69
10Y P/E Exit ₹48.13 ₹55.02 ₹60.36 64
Earnings-Based
Graham-Dodd ₹4.97 ₹6.07 ₹6.83 67
Multiples
P/E Multiple ₹9.31 ₹12.42 ₹15.52 63
P/S Multiple ₹9.31 ₹12.42 ₹15.52 57
P/B Multiple ₹20.43 ₹27.24 ₹34.05 55
Asset-Based
NCAV (Graham) ₹22.71 ₹34.41 ₹43.02 54
Growth DCF
Growth DCF ₹78.81 ₹105.00 ₹143.17 78
Rev-Margin DCF ₹26.52 ₹41.56 ₹62.10 71
Economic Profit
Residual Income ₹42.26 ₹45.74 ₹49.96 71
Growth Earnings
Growth-Adj P/E ₹6.64 ₹9.48 ₹12.32 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 33
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 82
Do the profits arrive as real cash?
Financial strength 6
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 62
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Start year 2021 (pandemic). Over 10 years: −12.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
What shareholders gained per year (last 3 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−51.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−51.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
⚠ Revenue per share shrinking 14.8%/yr over ~8Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

526853 screens overvalued: fair value 48% below the price. Compare with DAIOS →

Compare Bilcare Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Containers & Packaging · 25 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −47.9% · Below median
Profitability
Return on assets 0.9% · Below median
Net margin (12 months) 57.6% · Top 25%
Operating margin (12 months) 1.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −76.9% · Bottom 25%
Balance sheet
Debt / equity 2.29× · Highest 25%

Valuation Multiplesvs Containers & Packaging median · lower = cheaper

P/B 1.03× · Pricier than median
P/S (12 months) 1.19× · Priciest 25%
Price / free cash flow (fiscal year) 7.3× · Cheapest 25%
EV/EBITDA 150.1× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Containers & Packaging stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
HPBL HPBL ₹235.75 ₹379.03 +61% vs 526853
GUJCONT GUJCONT ₹152.10 ₹221.80 +46% vs 526853
JUMBO JUMBO ₹84.75 ₹105.75 +25% vs 526853
Daelim Paper Co 017650 2,010 KRW 2,417 KRW +20% vs 526853
HINDTIN HINDTIN ₹128.75 ₹135.91 +6% vs 526853
DAIOS DAIOS €7.25 €6.43 −11% vs 526853
RDBRL RDBRL ₹130.95 ₹104.53 −20% vs 526853
ECOPLAST ECOPLAST ₹460.30 ₹361.00 −22% vs 526853
M2N Co 033310 1,188 KRW 753.29 KRW −37% vs 526853
542019 542019 ₹25.66 ₹4.57 −82% vs 526853

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bilcare Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bilcare Limited Fair Value". https://www.fairvalue-calculator.com/stock/526853

Frequently asked questions

Is Bilcare Limited (526853) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹44.81 versus a price of ₹86.07, about 48% lower (overvalued).
What is the fair value of 526853?
Our model-based fair value for Bilcare Limited is ₹44.81 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹86.07.
What is the quality score of 526853?
Bilcare Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bilcare Limited (526853)?
Our model-based price target is the fair value of ₹44.81 (as of Nov 12, 2026) from 17 valuation models. Cautious scenario ₹30.48, optimistic scenario ₹49.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Bilcare Limited stock forecast for 2026?
Our models put fair value at ₹44.81, about 48% lower versus a price of ₹86.07 (overvalued). Cautious scenario ₹30.48, optimistic scenario ₹49.96. The calculation is refreshed regularly with new filings.
What is the revenue of Bilcare Limited (526853)?
Bilcare Limited reported trailing-twelve-month revenue of about ₹7.2B (latest available figure, as of Nov 12, 2026).
What is the intrinsic value of Bilcare Limited (526853)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bilcare Limited it is ₹44.81 per share (as of Nov 12, 2026), against a price of ₹86.07. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bilcare Limited stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 526853 trades above its calculated fair value: price ₹86.07, fair value ₹44.81, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 526853?
No. The price is what the market pays today (₹86.07); the fair value is what the company's own numbers justify (₹44.81). For Bilcare Limited the two are ₹41.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bilcare Limited worth?
The market values Bilcare Limited at about ₹2.0B (market capitalisation, as of Nov 12, 2026). Per share that is ₹86.07; our models calculate a fair value of ₹44.81 per share.
What do the bullish and bearish scenarios say about 526853?
Our models span a range for Bilcare Limited: cautious scenario ₹30.48, base ₹44.81, optimistic ₹49.96 per share (as of Nov 12, 2026, price ₹86.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bilcare Limited (526853)?
Balance-sheet figures for Bilcare Limited (as of Nov 12, 2026): debt of 2.29 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 526853 from its 52-week high?
Bilcare Limited trades at ₹86.07, about 22% below its 52-week high of ₹110.90 and 66% above the low of ₹51.94 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹44.81 is for.
Which stocks are comparable to Bilcare Limited?
From the same area (Materials) we also value DAIOS, Daelim Paper Co, M2N Co, HPBL, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bilcare Limited stock attractive at the current price?
The data as of Nov 12, 2026: price ₹86.07, calculated fair value ₹44.81 (−48%), Quality Score 59/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 526853 calculated?
We run Bilcare Limited through 17 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹44.81 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Bilcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bilcare Limited (526853)?
The closing price on Nov 17, 2026 was ₹86.07. Our model-based fair value is ₹44.81, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bilcare Limited right now?
The price sits above even our optimistic bull case (₹49.96). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Bilcare Limited

How large is the market capitalisation of Bilcare Limited (526853)?
The market capitalisation of Bilcare Limited is ₹2.0B (≈ $21.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bilcare Limited (526853)?
The price-to-sales ratio of Bilcare Limited is 0.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bilcare Limited (526853)?
Earnings per share at Bilcare Limited are ₹41.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bilcare Limited (526853)?
The net margin of Bilcare Limited is 13.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Bilcare Limited (526853)?
On an EBIT basis the return on assets of Bilcare Limited is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bilcare Limited (526853)?
The operating margin of Bilcare Limited is 1.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bilcare Limited (526853)?
Revenue at Bilcare Limited is down 76.9% versus a year earlier (3y avg −9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bilcare Limited (526853) generate?
The free cash flow of Bilcare Limited is ₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bilcare Limited (526853) carry?
The net debt of Bilcare Limited is ₹6.0B (fiscal year 2026, ≈ 5.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bilcare Limited in the live analysis

One click puts Bilcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.